Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: A pilot study

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1903-1906

  Culine, Stéphane ^a   Rebillard, Xavier ^b   Iborra, Francois ^c   Mottet, Nicolas ^d   Faix, Antoine ^b   Ayuso, Didier ^e   Pinguet, Frédéric ^a  

^a CENTRE VAL D AURELLE   (France)

^b Clinique Beausoleil   (France)

^c CLINIQUE DU PARC   (France)

^d NÎMES UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER   (France)

Author keywords

Gemcitabine; Oxaliplatin; Urothelial cancer

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DIARRHEA; DRUG DOSE REDUCTION; FEASIBILITY STUDY; HEART INFARCTION; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; TASK PERFORMANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PILOT PROJECTS; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 0038538449     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Saxman SB, Propert KJK, Einhorn LH et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a coooperative group study. J Clin Oncol 15: 2564-2569, 1997.
2. Sternberg CN, de Mulder PHM, Schornagel JH et al: Randomized phase III trial of high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and treatment of Cancer protocol n 30924. J Clin Oncol 19: 2638-2646, 2001.
3. Von der Maase H, Hansen SW, Roberts JT et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077, 2000.
4. Igawa M, Kaneda H, Ueda M and Usui T: Association between patient characteristics and treatment history, and toxicity associated with methotrexate, vinblastine, adriamycin and cisplatin (MVAC) for advanced urothelial cancer. Br J Urol 73: 263-267, 1994.
5. Fossa SD, Sternberg C, Scher HI et al: Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 74: 1655-1659, 1996.
6. Von der Maase H: Gemcitabine in locally advanced and/or metastatic bladder cancer. Crit Rev Oncol Hematol 34: 175-184, 2000.
7. Raymond E, Chaney SG, Taama A and Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9: 1053-1071, 1998.
8. Faivre S, Raymond E, Woynarowski JM and Cvitkovic E: Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44: 117-123, 1999.
9. Miller AB, Hoogstraten B, Staquet B and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
10. Faivre S, Raymond E, Lokiec F et al: Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13: 1479-1489, 2002.
11. Louvet C, André T, Lledo G et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20: 1512-1518, 2002.
12. Alberts SR, Townley PM, Goldberg RM et al: Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group phase I study. Ann Oncol 13: 553-557, 2002.
13. Carles J, Nogué M, Domenech M et al: Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59: 24-27, 2000.
14. Shannon C, Crombie C, Brooks A et al: Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol 12: 947-952, 2001.
15. Bellmunt J, Wit R, Alnabell J and Baselga J: A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 37: 2212-2215, 2001.
16. Massari C, Brienza S, Ritarski M et al: Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45: 157-164, 2000.